Comparison of Short-term Outcomes Between Faricimab and High-Dose Aflibercept in Patients With Neovascular Age-related Macular Degeneration. [PDF]
Shiratori M +4 more
europepmc +1 more source
Short term real-world effectiveness of faricimab in neovascular age-related macular degeneration patients in the Republic of Korea. [PDF]
Chung DH +8 more
europepmc +1 more source
Therapeutic Equivalence of Eyluxvi (Aflibercept) to Eylea in Neovascular Age-Related Macular Degeneration: ALTERA Trial (Randomized). [PDF]
Raczynska D +18 more
europepmc +1 more source
Efficacy of Faricimab in Neovascular Age-Related Macular Degeneration: A Single-Arm Systematic Review and Meta-Analysis. [PDF]
Karam M +7 more
europepmc +1 more source
A systematic review on the effect of bevacizumab in exudative age-related macular degeneration [PDF]
core +1 more source
Real-world treatment outcomes of aflibercept versus bevacizumab for neovascular age-related macular degeneration. [PDF]
Mhmud H +8 more
europepmc +1 more source
Integrating genetics, age and imaging to predict treatment outcomes in neovascular age-related macular degeneration: a proof-of-concept study. [PDF]
Moghul I +15 more
europepmc +1 more source
Intestinal Microbiome of Newly Diagnosed Patients With Neovascular Age-Related Macular Degeneration: A 16S rRNA Gene Sequencing Study. [PDF]
Katsanos A +8 more
europepmc +1 more source
Initial Experiences of Switching to Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration and Polypoidal Chorodal Vasculopathy in an Asian Population. [PDF]
Cheung CMG, Kikushima W, Teo KYC.
europepmc +1 more source

